Articles by Walter Armstrong - Pharmaceutical Executive

ADVERTISEMENT
Articles by Walter Armstrong
« Previous
12345678
Next »

Lupus: How Big will Benlysta Become?

Dec 1, 2010
By: Walter Armstrong

Pharm Exec's Pipeline Report 2022

Hyperlipidemia: The Anti-CETPs Redux

Dec 1, 2010
By: Walter Armstrong

Pharm Exec's Pipeline Report 2011

Rheumatoid Arthritis: JAKing Down Inflammation

Dec 1, 2010
By: Walter Armstrong

Pharm Exec's Pipeline Report 2023

Cancer: On Target Once More

Dec 1, 2010
By: Walter Armstrong

Pharm Exec's Pipeline Report 2019

Acute Coronary Syndrome

Dec 1, 2010
By: Walter Armstrong

Pharm Exec's Pipeline Report 2012

Non-Small-Cell Lung Cancer: Targeting Pathways and Patients

Dec 1, 2010
By: Walter Armstrong

Pharm Exec's Pipeline Report 2020

Nicotine Addiction: What Lights Up the Field

Dec 1, 2010
By: Walter Armstrong

Pharm Exec's Pipeline Report 2018

Multiple Sclerosis: The Advent of the Orals

Dec 1, 2010
By: Walter Armstrong

Pharm Exec's Pipeline Report 2021

Science and Politics at the FDA

Nov 1, 2010
By: Walter Armstrong

Harvard professor Daniel Carpenter offers a piercing analysis of the FDA and sheds light on its biggest challenges

« Previous
12345678
Next »

ADVERTISEMENT

Click here